[
1. Jemal A, Center MM, De Santis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarker Prev 2010; 19(8):1893-907.10.1158/1055-9965.EPI-10-0437
]Search in Google Scholar
[
2. NCCN Guidelines Version 1.2018. Prostate cancer. January 2018.
]Search in Google Scholar
[
3. Brundage M, Lukka H, Crook J, et al. The use of conformal radiotherapy ant the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer- a systematic review. Radiother Oncol 2002; 64(3):12.10.1016/S0167-8140(02)00184-6
]Search in Google Scholar
[
4. Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73(3):685-691.10.1016/j.ijrobp.2008.04.063
]Search in Google Scholar
[
5. Kuban DA, Tucker SL, Dong L et al. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70:67–74.10.1016/j.ijrobp.2007.06.054
]Search in Google Scholar
[
6. Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, et al. 70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial. Int J Radiat Oncol Biol Phys 2011; 80: 1056–1063.10.1016/j.ijrobp.2010.03.049
]Search in Google Scholar
[
7. Sujenthiran A, Nossiter J, Charman SC, et al. National population-based study comparing treatment-related toxicity in men who received intensity modulated versus 3-dimensional conformal radical radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2017;99:1253-60.10.1016/j.ijrobp.2017.07.040
]Search in Google Scholar
[
8. Gary Luxton, Steven L. Hancock, Arthur L. Boyer. Dosimetry and radiobiological model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2004, 59 :(1): 267–284.10.1016/j.ijrobp.2004.01.024
]Search in Google Scholar
[
9. H.V. James, C.D. Scrase, A.J. Poynter. Practical experience with intensity-modulated radiotherapy. Br J Radiol 2004; 77: 3–14.10.1259/bjr/14996943
]Search in Google Scholar
[
10. Edges SB, Byrd DR, Compton CC.AJCC Cancer Staging Handbook. 7th edition. New York, NY: Springer 2010.
]Search in Google Scholar
[
11. Litzenburg D, Dawson AD, Sandler H, et al. Daily prostate targeting using implanted radiopaque markers. Int J Radiat Oncol Biol Phys. 2002; 52(3):699–703.10.1016/S0360-3016(01)02654-2
]Search in Google Scholar
[
12. Poggi MM, Gant DA, Sewchand W, Warlick WB. Marker seed migration in prostate localization. Int J Radiat Oncol Biol Phys. 2003; 56(5):1248–1251.10.1016/S0360-3016(03)00328-6
]Search in Google Scholar
[
13. Drzamala RE,Mohan R, Brewster L, Chu J, Goitein M, Harms W, et al. Dose volume Histograms. Int J Radiat Oncol Biol Phys 1991; 21:71-78.10.1016/0360-3016(91)90168-4
]Search in Google Scholar
[
14. Cox JD et al.Toxicity criteria of Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31(5):1341-1346.10.1016/0360-3016(95)00060-C
]Search in Google Scholar
[
15. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam intensity-modulated radiation therapy. ICRU Report 83. Bethesda, MD: ICRU; 2010.
]Search in Google Scholar
[
16. Feuvret L, Noel G, Mazeron JJ, Bey P. Conformity index- a review. Int J Radiat Oncol Biol Phys 2006; 64:333–42.10.1016/j.ijrobp.2005.09.028
]Search in Google Scholar
[
17. Yoon M, Park SY, Shin D, Lee SB, Pyo HR, Kim DY et al:A new homogeneity index based on statistical analysis of the dose-volumehistogram.J Appl Clin Med Phys 2007;8:(2):9-17.10.1120/jacmp.v8i2.2390
]Search in Google Scholar
[
18. Stangerberger A, Waldert M, Djuvan B. Prostate Cancer in elderly men. Rev Urol 2008; 10(2):111-119.
]Search in Google Scholar
[
19. Viani GA, Stefano EJ, Alfonso SL et al. Higher than conventional radiation doses in localized prostate treatment: A meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74(5):1405-18.10.1016/j.ijrobp.2008.10.091
]Search in Google Scholar
[
20. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M.D.Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53 (5):1097-1105.10.1016/S0360-3016(02)02829-8
]Search in Google Scholar
[
21. Zietman AL, De Silvio MR, Slater JD et al. Comparison of conventional dose vs. high dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 2005; 294: 1233-1239.10.1001/jama.294.10.1233
]Search in Google Scholar
[
22. Vincent W.C. Wu, Dora L.W. Kwong, Jonathan S.T. Sham. Target dose conformity in 3-dimensional conformal radiotherapy and intensity modulated radiotherapy Radiat Oncol 2004; 71: 201–206.
]Search in Google Scholar
[
23. Gert De Meerleer, Luc Vakaet, Werner R.T. De Gersem, et al. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison Int J Radiat Oncol Biol Phys 2000; 47: (3) :639–648.10.1016/S0360-3016(00)00419-3
]Search in Google Scholar
[
24. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three dimensional conformal radiotherapy and intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70(4): 1124-1129.10.1016/j.ijrobp.2007.11.04418313526
]Search in Google Scholar
